Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Want to see CRBP full AI Analyst Report?
Top Page
Corbus Pharmaceuticals
(NASDAQ:CRBP)
Select Model
Select Model
Rating:60Neutral
Price Target:
$12.00
▲(13.31% Upside)
Action:Reiterated
Date:05/27/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and increasing cash burn). Offsetting this are constructive technical momentum (price above key moving averages with positive MACD) and positive corporate catalysts, including FDA-aligned registrational planning and encouraging CRB-701 clinical updates.
Positive Factors
FDA alignment for CRB-701 registrational path
Regulatory alignment materially lowers execution risk for late-stage development: clear endpoints (ORR for potential accelerated approval, OS for full approval) and single randomized trial designs enable definitive protocol planning, faster trial starts (summer 2026) and a more predictable route to approval if efficacy is confirmed.
Negative Factors
Pre-revenue with widening losses
The absence of product revenue and materially larger net losses reflect a classic pre-commercial biotech profile that depends on capital markets. Persistent negative profitability erodes equity over time and means the company must convert clinical success into commercialization or recurring partnership revenue to achieve sustainable economics.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA alignment for CRB-701 registrational path
Regulatory alignment materially lowers execution risk for late-stage development: clear endpoints (ORR for potential accelerated approval, OS for full approval) and single randomized trial designs enable definitive protocol planning, faster trial starts (summer 2026) and a more predictable route to approval if efficacy is confirmed.
Read all positive factors
Corbus Pharmaceuticals (CRBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$141.55M
Dividend YieldN/A
Average Volume (3M)503.64K
Price to Earnings (P/E)―
Beta (1Y)1.62
Revenue GrowthN/A
EPS Growth-37.60%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.31
Shares Outstanding18,527,796
10 Day Avg. Volume744,820
30 Day Avg. Volume503,638
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-476.04
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$38.67Price Target Upside265.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.64
Revenue Forecast (FY)$1.67M
Corbus Pharmaceuticals Business Overview & Revenue Model
Company Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor ...
How the Company Makes Money
Corbus primarily generates revenue from collaboration and licensing arrangements rather than from marketed product sales. Historically, this has included recognizing collaboration-related revenue (e.g., upfront payments and/or other amounts associ...
Corbus Pharmaceuticals Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
66
Positive
Cash Flow
23
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 881.71K |
| Gross Profit | -149.00K | 0.00 | -600.00K | 0.00 | -1.49M | -757.53K |
| EBITDA | -85.66M | -78.30M | -37.74M | -40.10M | -38.73M | -54.35M |
| Net Income | -84.53M | -78.54M | -40.21M | -44.60M | -55.83M | -45.55M |
Balance Sheet | ||||||
| Total Assets | 144.48M | 168.19M | 155.88M | 28.27M | 66.31M | 107.73M |
| Cash, Cash Equivalents and Short-Term Investments | 138.60M | 163.94M | 149.06M | 20.91M | 59.20M | 97.65M |
| Total Debt | 1.21M | 1.63M | 3.24M | 20.89M | 25.09M | 26.59M |
| Total Liabilities | 18.14M | 20.69M | 13.45M | 35.18M | 33.32M | 38.62M |
| Stockholders Equity | 126.34M | 147.50M | 142.43M | -6.91M | 32.99M | 69.11M |
Cash Flow | ||||||
| Free Cash Flow | -73.65M | -64.50M | -41.79M | -36.10M | -37.56M | -48.24M |
| Operating Cash Flow | -73.64M | -64.49M | -41.79M | -36.10M | -37.54M | -48.18M |
| Investing Cash Flow | 2.69M | -1.64M | -121.31M | 35.64M | 30.07M | -73.42M |
| Financing Cash Flow | 77.43M | 77.43M | 166.58M | -2.82M | -533.62K | 60.82M |
Corbus Pharmaceuticals Technical Analysis
Negative
10.59
Price Trends
9.91
Negative
9.15
Negative
10.36
Negative
Market Momentum
-0.50
Positive
37.39
Neutral
5.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBP, the sentiment is Negative. The current price of 10.59 is above the 20-day moving average (MA) of 10.24, above the 50-day MA of 9.91, and above the 200-day MA of 10.36, indicating a bearish trend. The MACD of -0.50 indicates Positive momentum. The RSI at 37.39 is Neutral, neither overbought nor oversold. The STOCH value of 5.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBP.
Corbus Pharmaceuticals Risk Analysis
Corbus Pharmaceuticals disclosed 51 risk factors in its most recent earnings report. Corbus Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Corbus Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $141.55M | -1.25 | -70.89% | ― | ― | -37.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $44.69M | -1.20 | -84.91% | ― | ― | -40.23% | |
48 Neutral | $99.77M | -2.22 | -196.72% | ― | ― | 74.83% | |
43 Neutral | $70.58M | -1.13 | -91.94% | ― | 106.65% | 12.20% |
* Healthcare Sector Average
CRBP
Corbus Pharmaceuticals
7.91
0.49
6.60%
ATOS
Atossa Therapeutics
5.23
-6.43
-55.13%
BMEA
Biomea Fusion
1.38
-0.06
-4.17%
TCRX
TScan Therapeutics
1.08
-0.35
-24.48%
Corbus Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Corbus Highlights Promising CRB-701 Data in HPV Cancers
Positive
May 26, 2026
On May 26, 2026, Corbus reported updated Phase 1/2 data showing that its Nectin-4–targeted ADC CRB-701 delivered confirmed objective response rates of 42.9% in second-line oropharyngeal squamous cell carcinoma and 34.4% in second-line cervic...
Business Operations and StrategyExecutive/Board Changes
Corbus Pharmaceuticals Appoints First Chief Business Officer
Positive
May 21, 2026
On May 21, 2026, Corbus Pharmaceuticals appointed former Evercore managing director Nishant Saxena as its first Chief Business Officer under a two-year employment agreement that runs through May 21, 2028. His package includes a $470,000 base salar...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates
Positive
May 14, 2026
On May 13, 2026, Corbus Pharmaceuticals’ board appointed veteran pharma executive Brent Pfeiffenberger to its board of directors, expanding the board to seven members and classifying him as an independent director under Nasdaq rules. Pfeiffe...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Corbus Highlights Oncology, Obesity Pipeline Progress and Outlook
Positive
May 12, 2026
On May 12, 2026, Corbus Pharmaceuticals reported first-quarter 2026 results and a corporate update, highlighting momentum in its oncology and obesity pipelines. The company reached broad alignment with the U.S. Food and Drug Administration on the ...
Business Operations and StrategyExecutive/Board Changes
Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections
Positive
Apr 16, 2026
On April 15, 2026, Corbus Pharmaceuticals entered into amended and restated employment agreements with Chief Executive Officer Yuval Cohen and Chief Financial Officer Sean Moran, setting new two-year terms through April 15, 2028 with increased cla...
Business Operations and StrategyProduct-Related Announcements
Corbus Advances CANYON-1 Phase 1b Obesity Trial Milestone
Positive
Apr 14, 2026
On April 14, 2026, Corbus Pharmaceuticals announced that the last patient had been enrolled and completed the first clinical visit in its CANYON-1 Phase 1b trial of CRB-913 for obesity, keeping the 16-week dose-finding study on schedule for comple...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Corbus Aligns With FDA on CRB-701 Registrational Path
Positive
Apr 7, 2026
On April 7, 2026, Corbus Pharmaceuticals announced it had reached broad alignment with the U.S. Food and Drug Administration on the registration path for its Nectin-4 targeting antibody-drug conjugate CRB-701 in second-line head and neck squamous ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress
Positive
Mar 9, 2026
On March 9, 2026, Corbus Pharmaceuticals reported fourth-quarter and full-year 2025 results, highlighting strong clinical progress across its pipeline and a bolstered balance sheet. In oncology, Q4 2025 Phase 1/2 data for CRB-701 in head and neck ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.